The significance of strong histone deacetylase 1 expression in the progression of prostate cancer

Histopathology

Volumn 58, Issue 5, 2011, Pages 773-780

  Song, Yoohyun ^a,b   Shiota, Masaki ^b   Tamiya, Sadafumi ^a   Kuroiwa, Kentaro ^b   Naito, Seiji ^b   Tsuneyoshi, Masazumi ^a  

^a Department of Anatomic Pathology ^*  (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Histone deacetylase 1; Immunohistochemistry; Progression; Prostate cancer

Indexed keywords

HISTONE DEACETYLASE 1;

AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CORRELATION ANALYSIS; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION;

AGED; DISEASE PROGRESSION; HISTONE DEACETYLASE 1; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS;

EID: 79954591057     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03797.x     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin. 2007; 57; 43-66.
2. Parkin DM. Global cancer statistics in the year 2000. The Lancet Oncology 2001; 2; 533-543.
3. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J. Urol. 2003; 169; 517-523.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100; 57-70.
5. Rennie PS, Nelson CC. Epigenetic mechanisms for progression of prostate cancer. Cancer and Metastasis Reviews 1998; 17; 401-409.
6. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007; 26; 5420-5432.
7. Sambucetti LC, Fischer DD, Zabludoff S et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. Journal of Biological Chemistry 1999; 274; 34940-34947.
8. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA 2000; 97; 10014-10019.
9. Lagger G, O'Carroll D, Rembold M et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 2002; 21; 2672-2681.
10. Augenlicht L, Shi L, Mariadason J, Laboisse C, Velcich A. Repression of MUC2 gene expression by butyrate, a physiological regulator of intestinal cell maturation. Oncogene 2003; 22; 4983-4992.
11. Caslini C, Capo-chichi CD, Roland IH, Nicolas E, Yeung AT, Xu XX. Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene 2006; 25; 5446-5461.
12. Kim MS, Kwon HJ, Lee YM et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 2001; 7; 437-443.
13. Deroanne CF, Bonjean K, Servotte S et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002; 21; 427-436.
14. Crazzolara R, Johrer K, Johnstone RW et al. Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. Br. J. Haematol. 2002; 119; 965-969.
15. Conley BA, Wright JJ, Kummar S. Targeting epigenetic abnormalities with histone deacetylase inhibitors. Cancer 2006; 107; 832-840.
16. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. 2006; 6; 38-51.
17. Banwell CM, Singh R, Stewart PM, Uskokovic MR, Campbell MJ. Antiproliferative signalling by 1, 25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation. Recent Results Cancer Res. Fortschritte der Krebsforschung 2003; 164; 83-98.
18. Patra SK, Patra A, Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem. Biophys. Res. Commun. 2001; 287; 705-713.
19. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004; 59; 177-189.
20. Shiota M, Izumi H, Onitsuka T et al. Twist and p53 reciprocally regulate target genes via direct interaction. Oncogene 2008; 27; 5543-5553.
21. Shiota M, Izumi H, Onitsuka T et al. Twist promotes tumor cell growth through YB-1 expression. Cancer Res. 2008; 68; 98-105.
22. Shiota M, Izumi H, Tanimoto A et al. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res. 2009; 69; 3148-3156.
23. Shiota M, Yokomizo A, Tada Y et al. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 2010; 29; 237-250.
24. Weichert W, Roske A, Gekeler V et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer 2008; 98; 604-610.
25. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998; 11; 155-168.
26. Waltregny D, North B, Van Mellaert F, De Leval J, Verdin E, Castronovo V. Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. Eur. J. Histochem. 2004; 48; 273-290.
27. Nakagawa M, Oda Y, Eguchi T et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol. Rep. 2007; 18; 769-774.
28. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 2001; 61; 8492-8497.
29. Floryk D, Huberman E. Differentiation of androgen-independent prostate cancer PC-3 cells is associated with increased nuclear factor-kappaB activity. Cancer Res. 2005; 65; 11588-11596.
30. Song J, Noh JH, Lee JH et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica 2005; 113; 264-268.
31. Weichert W, Roske A, Gekeler V et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncology 2008; 9; 139-148.